Common Contracts
11 similar Executive Employment Agreement contracts by Sagimet Biosciences Inc.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 14th, 2024 • Sagimet Biosciences Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (“Agreement”) is made between Sagimet Biosciences, Inc., (the “Company”), and George Kemble (the “Executive”) and is effective as of June 5, 2024 (the “Effective Date”). Except with respect to the Equity Documents and the Continuing Obligations (each, as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Executive Employment Agreement dated August 7, 2023, (ii) the Employment Agreement between the Executive and the Company dated June 27, 2011, as amended and restated on October 14, 2022, and (iii) any offer letter, as applicable (collectively, the “Prior Agreement”).
amended and restated EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 14th, 2024 • Sagimet Biosciences Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (“Agreement”) is made between Sagimet Biosciences, Inc., (the “Company”), and David Happel (the “Executive”) and is effective as of June 5, 2024 (the “Effective Date”). Except with respect to the Equity Documents and the Continuing Obligations (each, as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Executive Employment Agreement dated August 7, 2023, (ii) the Employment Agreement between the Executive and the Company dated October 3, 2022, and (iii) any offer letter, as applicable (collectively, the “Prior Agreement”).
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 14th, 2024 • Sagimet Biosciences Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (“Agreement”) is made between Sagimet Biosciences, Inc., (the “Company”), and Elizabeth Rozek (the “Executive”) and is effective as of June 5, 2024 (the “Effective Date”). Except with respect to the Equity Documents and the Continuing Obligations (each, as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Executive Employment Agreement dated August 7, 2023, (ii) the Employment Agreement between the Executive and the Company dated April 4, 2023, and (iii) any offer letter, as applicable (collectively, the “Prior Agreement”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 14th, 2024 • Sagimet Biosciences Inc. • Pharmaceutical preparations • California
This Employment Agreement (“Agreement”) is made between Sagimet Biosciences, Inc., (the “Company”), and Thierry Chauche (the “Executive”) and is effective as of May 6, 2024 (the “Effective Date”).
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 14th, 2024 • Sagimet Biosciences Inc. • Pharmaceutical preparations • California
This Amended and Restated Employment Agreement (“Agreement”) is made between Sagimet Biosciences, Inc., (the “Company”), and Eduardo Martins (the “Executive”) and is effective as of June 5, 2024 (the “Effective Date”). Except with respect to the Equity Documents and the Continuing Obligations (each, as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Executive Employment Agreement dated August 7, 2023, (ii) the Employment Agreement between the Executive and the Company dated February 9, 2021, and (iii) any offer letter, as applicable (collectively, the “Prior Agreement”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 21st, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations • California
This Employment Agreement (“Agreement”) is made between Sagimet Biosciences Inc., (the “Company”), and Elizabeth Rozek (the “Executive”) and is effective as of July 19, 2023 (the “Effective Date”). Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated April 4, 2023, and (ii) any offer letter, as applicable (collectively, the “Prior Agreement”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 21st, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations • California
This Employment Agreement (“Agreement”) is made between Sagimet Biosciences Inc., (the “Company”), and Anthony Rimac (the “Executive”) and is effective as of July 19, 2023 (the “Effective Date”). Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated April 4, 2023, and (ii) any offer letter, as applicable (collectively, the “Prior Agreement”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 21st, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations • California
This Employment Agreement (“Agreement”) is made between Sagimet Biosciences Inc., (the “Company”), and David Happel (the “Executive”) and is effective as of July 19, 2023 (the “Effective Date”). Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated October 3, 2022, and (ii) any offer letter, as applicable (collectively, the “Prior Agreement”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 21st, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations • California
This Employment Agreement (“Agreement”) is made between Sagimet Biosciences Inc., (the “Company”), and Eduardo Martins (the “Executive”) and is effective as of July 19, 2023 (the “Effective Date”). Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated February 9, 2021, and (ii) any offer letter, as applicable (collectively, the “Prior Agreement”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 21st, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations • California
This Employment Agreement (“Agreement”) is made between Sagimet Biosciences Inc., (the “Company”), and George Kemble (the “Executive”) and is effective as of July 19, 2023 (the “Effective Date”). Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated June 27, 2011, as amended and restated on October 14, 2022, and (ii) any offer letter, as applicable (collectively, the “Prior Agreement”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 23rd, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations • California
This Employment Agreement (“Agreement”) is made between Sagimet Biosciences, Inc., (the “Company”), and [·] (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”)]. Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated [·], and (ii) any offer letter, as applicable (collectively, the “Prior Agreement”).
